Sylvia L Asa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1637922/publications.pdf

Version: 2024-02-01

560 papers	38,175 citations	90 h-index	172 g-index
620 all docs	620 docs citations	620 times ranked	25165 citing authors

3515

4419

#	Article	IF	Citations
1	Pituitary corticotroph tumour with adrenocortical cells: A distinct clinicopathologic entity with unique morphology and methylation profile. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	0
2	Adrenal Gland. , 2022, , 461-486.		0
3	Letter to the Editor From Asa and Mete: â€œHypophysitis, the Growing Spectrum of a Rare Pituitary Diseaseâ€• Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2649-e2649.	1.8	3
4	The Next Steps for Endocrine Pathology. Endocrine Pathology, 2022, 33, 228-230.	5.2	2
5	Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology, 2022, 33, 27-63.	5.2	388
6	Overview of the 2022 WHO Classification of Pituitary Tumors. Endocrine Pathology, 2022, 33, 6-26.	5.2	174
7	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology, 2022, 33, 115-154.	5.2	227
8	Pituitary carcinoma: reclassification and implications in the NET schema. Endocrine Oncology, 2022, 2, R14-R23.	0.1	3
9	Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocrine Pathology, 2022, 33, 90-114.	5.2	115
10	Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. Modern Pathology, 2022, 35, 712-720.	2.9	17
11	The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). Current Issues in Molecular Biology, 2022, 44, 2015-2028.	1.0	5
12	The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. Modern Pathology, 2022, 35, 1570-1577.	2.9	6
13	Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 83-97.	1.1	21
14	Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion. Head and Neck Pathology, 2021, 15, 628-637.	1.3	1
15	Endoscopic Endonasal Pituitary Surgery For Nonfunctioning Pituitary Adenomas: Long-Term Outcomes and Management of Recurrent Tumors. World Neurosurgery, 2021, 146, e341-e350.	0.7	10
16	Cytokeratin profiles in pituitary neuroendocrine tumors. Human Pathology, 2021, 107, 87-95.	1.1	21
17	Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates. Endocrine Pathology, 2021, 32, 77-101.	5.2	21
18	Pathology of pituitary growth hormone excess. , 2021, , 17-37.		0

#	Article	IF	Citations
19	Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors. Endocrine Pathology, 2021, 32, 169-191.	5.2	26
20	The Pangenomic Classification of Pituitary Neuroendocrine Tumors: Quality Histopathology is Required for Accurate Translational Research. Endocrine Pathology, 2021, 32, 415-417.	5.2	9
21	Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease. Frontiers in Endocrinology, 2021, 12, 620005.	1.5	6
22	Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas. American Journal of Surgical Pathology, 2021, 45, 1264-1273.	2.1	19
23	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas, 2021, 50, 469-493.	0.5	55
24	Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors. Endocrine Pathology, 2021, 32, 222-227.	5.2	7
25	Oncocytic Change in Thyroid Pathology. Frontiers in Endocrinology, 2021, 12, 678119.	1.5	18
26	Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Modern Pathology, 2021, 34, 1634-1650.	2.9	44
27	Middle Ear â€œAdenomaâ€• a Neuroendocrine Tumor with Predominant L Cell Differentiation. Endocrine Pathology, 2021, 32, 433-441.	5.2	15
28	An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism. Journal of Clinical Medicine, 2021, 10, 2254.	1.0	15
29	Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. Endocrine Pathology, 2021, 32, 327-335.	5.2	25
30	Pendred Syndrome with C Cell Hyperplasia. Endocrine Pathology, 2021, 32, 427-428.	5.2	1
31	Follicular cells in pituitary neuroendocrine tumors. Human Pathology, 2021, 114, 1-8.	1.1	4
32	Nasopharyngeal neuroendocrine neoplasms: Systematic review of the literature and case presentation. Journal of Neuroendocrinology, 2021, 33, e13005.	1.2	4
33	Single-cell transcriptome and genome analysis: A much-needed tool for pituitary neuroendocrine tumor studies. Neuro-Oncology, 2021, 23, 1803-1804.	0.6	0
34	XB130 Deficiency Causes Congenital Hypothyroidism in Mice due to Disorganized Apical Membrane Structure and Function of Thyrocytes. Thyroid, 2021, 31, 1650-1661.	2.4	5
35	Hypothalamic hormone-producing tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 181, 67-74.	1.0	2
36	Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?. Endocrine Pathology, 2021, 32, 3-16.	5.2	15

#	Article	IF	Citations
37	Metastatic Neuroendocrine Neoplasms of Unknown Primary Site. , 2021, , 357-387.		13
38	Genetic and epigenetic characterization of posterior pituitary tumors. Acta Neuropathologica, 2021, 142, 1025-1043.	3.9	7
39	Neuroendocrine Neoplasms: Historical Background and Terminologies. , 2021, , 1-14.		2
40	Pancreatic Neuroendocrine Neoplasms. , 2021, , 245-261.		0
41	Paragangliomas and Pheochromocytomas. , 2021, , 263-285.		1
42	Pituitary Neuroendocrine Neoplasms. , 2021, , 55-83.		2
43	Thyroid Neuroendocrine Neoplasms. , 2021, , 119-136.		2
44	Parathyroid Neuroendocrine Neoplasms. , 2021, , 137-150.		0
45	Pathogenesis of multinodular goiter in elderly XB130 deficient mice: alteration of thyroperoxidase affinity with iodide and hydrogen peroxide. Thyroid, 2021, , .	2.4	2
46	Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome. Frontiers in Endocrinology, 2021, 12, 795184.	1.5	11
47	Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution. Pituitary, 2020, 23, 322-325.	1.6	34
48	Syndrome of Inappropriate Antidiuresis in a Young Adultâ€"Searching for the Causative Needle in the Proverbial Haystack. Kidney International Reports, 2020, 5, 231-234.	0.4	2
49	Characterization of pathological thyroid tissue using polarization-sensitive second harmonic generation microscopy. Laboratory Investigation, 2020, 100, 1280-1287.	1.7	19
50	Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocrine Pathology, 2020, 31, 330-336.	5.2	24
51	Immunohistochemical Analysis of the Metabolic Phenotype of Adrenal Cortical Carcinoma. Endocrine Pathology, 2020, 31, 231-238.	5.2	7
52	Images in Endocrine Pathology: Progressive Loss of Sustentacular Cells in a Case of Recurrent Jugulotympanic Paraganglioma over a Span of 5 years. Endocrine Pathology, 2020, 31, 310-314.	5.2	8
53	Images in Endocrine Pathology: High-Grade Intrathyroidal Parathyroid Carcinoma with Crookeâ€™s Hyalinization. Endocrine Pathology, 2020, 31, 190-194.	5.2	2
54	Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor. Genome Medicine, 2020, 12, 38.	3.6	9

#	Article	IF	Citations
55	Thyroid Tumor Capsular Invasion: the Bottom Line or Much Ado About Nothing?. Endocrine Pathology, 2020, 31, 141-142.	5.2	4
56	Issues to Consider When Implementing Digital Pathology for Primary Diagnosis. Archives of Pathology and Laboratory Medicine, 2020, 144, 1297-1297.	1.2	4
57	Acidophil Stem Cell Tumor, Pituitary. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
58	Gonadotroph Tumor. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
59	Parathyroid Hyperplasia. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
60	Corticotroph Tumour. Encyclopedia of Pathology, 2020, , 1-6.	0.0	0
61	Pituitary Carcinoma. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
62	Null Cell Tumor. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
63	Mammosomatotroph Tumor. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
64	GATA2. Encyclopedia of Pathology, 2020, , 1-2.	0.0	0
65	Parathyroid Adenoma. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
66	C-Cell Hyperplasia. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
67	Lactotroph Tumor. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
68	Pituitary Neuroendocrine Tumor. Encyclopedia of Pathology, 2020, , 1-5.	0.0	0
69	Medullary Thyroid Carcinoma. Encyclopedia of Pathology, 2020, , 1-5.	0.0	0
70	Molecular profiling confirms historical immunohistochemistry in acromegaly. Endocrine-Related Cancer, 2020, 27, L1-L2.	1.6	0
71	Comprehensive characterization of a Canadian cohort of von Hippelâ€Lindau disease patients. Clinical Genetics, 2019, 96, 461-467.	1.0	16
72	VEGFRâ€2 is downregulated in sestamibiâ€negative parathyroid adenomas. Head and Neck, 2019, 41, 3564-3569.	0.9	4

#	Article	IF	Citations
73	A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology. Endocrine Pathology, 2019, 30, 201-218.	5.2	24
74	The Clinicopathological Spectrum of Parathyroid Carcinoma. Frontiers in Endocrinology, 2019, 10, 731.	1.5	25
75	Somatostatin Receptor Ligand Therapyâ€"A Potential Therapy for Neurocytoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2395-2402.	1.8	7
76	Diagnosis and Pathologic Characteristics of Medullary Thyroid Carcinomaâ€"Review of Current Guidelines. Current Oncology, 2019, 26, 338-344.	0.9	65
77	Hypothalamic Endocrine Tumors: An Update. Journal of Clinical Medicine, 2019, 8, 1741.	1.0	15
78	An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. Endocrine Pathology, 2019, 30, 118-127.	5.2	43
79	The Current Histologic Classification of Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 1-22.	1.2	66
80	Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. Annals of Surgical Oncology, 2019, 26, 2533-2539.	0.7	18
81	Treatment Options for Pancreatic Neuroendocrine Tumors. Cancers, 2019, 11, 828.	1.7	55
82	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. British Journal of Cancer, 2019, 120, 1113-1119.	2.9	83
83	Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging. Thyroid, 2019, 29, 619-624.	2.4	22
84	Characterization of Pancreatic Cancer Tissue Using Multiphoton Excitation Fluorescence and Polarization-Sensitive Harmonic Generation Microscopy. Frontiers in Oncology, 2019, 9, 272.	1.3	32
85	Molecular Predictors of Clinical Behavior in Pituitary Adenohypophysial Tumors. Contemporary Endocrinology, 2019, , 155-172.	0.3	0
86	Hypothalamic Vasopressin-Producing Tumors. American Journal of Surgical Pathology, 2019, 43, 251-260.	2.1	24
87	The Clinicopathological Spectrum of Acromegaly. Journal of Clinical Medicine, 2019, 8, 1962.	1.0	42
88	Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: a Possible Stem Cell Phenomenon. Endocrine Pathology, 2019, 30, 74-80.	5.2	25
89	GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Modern Pathology, 2019, 32, 484-489.	2.9	48
90	2020 Vision of Digital Pathology in Action. Journal of Pathology Informatics, 2019, 10, 27.	0.8	12

#	Article	IF	Citations
91	Ki67 Quantitative Interpretation: Insights using Image Analysis. Journal of Pathology Informatics, 2019, 10, 8.	0.8	23
92	SUN-453 Absence of Crooke's Hyaline Changes May Predict Worse Outcomes in Patients with Cushing Disease. Journal of the Endocrine Society, 2019, 3, .	0.1	0
93	Immunohistochemical Biomarkers in Pituitary Pathology. Endocrine Pathology, 2018, 29, 130-136.	5.2	26
94	Noninvasive Follicular Thyroid Neoplasm with Papillaryâ€Like Nuclear Features (NIFTP): Trading Six for a Risky Half Dozen: Reply. World Journal of Surgery, 2018, 42, 2279-2279.	0.8	4
95	Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Modern Pathology, 2018, 31, 900-909.	2.9	120
96	The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Human Pathology, 2018, 74, 1-4.	1.1	45
97	Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms. Endocrine Pathology, 2018, 29, 137-149.	5.2	45
98	Pancreatic Neuroendocrine Tumor Producing Insulin and Vasopressin. Endocrine Pathology, 2018, 29, 15-20.	5.2	9
99	Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications. Molecular and Cellular Endocrinology, 2018, 469, 70-76.	1.6	27
100	The epigenetic landscape of differentiated thyroid cancer. Molecular and Cellular Endocrinology, 2018, 469, 3-10.	1.6	24
101	Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2018, 42, 201-213.	2.1	56
102	Clinical Safety of Renaming Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: Is NIFTP Truly Benign?. World Journal of Surgery, 2018, 42, 321-326.	0.8	114
103	Integrated Pathology Informatics Enables High-Quality Personalized and Precision Medicine: Digital Pathology and Beyond. Archives of Pathology and Laboratory Medicine, 2018, 142, 369-382.	1.2	29
104	The retrotransposon gag domain containing protein Rgag4 is an Ikaros target in the pituitary. Molecular and Cellular Endocrinology, 2018, 461, 188-193.	1.6	4
105	What's new in pituitary pathology?. Histopathology, 2018, 72, 133-141.	1.6	24
106	Endocrine pathology: past, present and future. Pathology, 2018, 50, 111-118.	0.3	23
107	Intrathyroidal Parathyroid Carcinoma: An Atypical Thyroid Lesion. Frontiers in Endocrinology, 2018, 9, 641.	1.5	19
108	Pituitary Tumors; Diagnosis and Treatment. , 2018, , 257-257.		0

#	Article	IF	Citations
109	An Unusual Salivary Gland Tumor Mimicking Papillary Thyroid Carcinoma: Mammary Analog Secretory Carcinoma. Frontiers in Endocrinology, 2018, 9, 555.	1.5	9
110	The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. Journal of Clinical Medicine, 2018, 7, 280.	1.0	104
111	Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. Endocrine Pathology, 2018, 29, 332-338.	5.2	28
112	Immunohistochemical Biomarkers in Thyroid Pathology. Endocrine Pathology, 2018, 29, 91-112.	5.2	48
113	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 2018, 31, 1770-1786.	2.9	739
114	Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome. AACE Clinical Case Reports, 2018, 4, e289-e293.	0.4	0
115	Molecular Pathogenesis of Pituitary Tumors. , 2017, , 165-175.		0
116	Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases. Endocrine-Related Cancer, 2017, 24, L21-L25.	1.6	37
117	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	7.7	532
118	Pituitary acromegaly: not one disease. Endocrine-Related Cancer, 2017, 24, C1-C4.	1.6	37
119	Pancreatic Struma with Papillary Thyroid Carcinoma: a Diagnostic Dilemma. Endocrine Pathology, 2017, 28, 91-94.	5.2	2
120	The evolution of differentiated thyroid cancer. Pathology, 2017, 49, 229-237.	0.3	20
121	From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocrine-Related Cancer, 2017, 24, C5-C8.	1.6	262
122	The dangers of parathyroid biopsy. Journal of Otolaryngology - Head and Neck Surgery, 2017, 46, 4.	0.9	44
123	Xanthomatous Hypophysitis Is Associated with Ruptured Rathkeâ€™s Cleft Cyst. Endocrine Pathology, 2017, 28, 83-90.	5.2	31
124	Pituitary Adenomas Presenting as Sinonasal or Nasopharyngeal Masses. American Journal of Surgical Pathology, 2017, 41, 525-534.	2.1	26
125	Pathologic Reporting of Tall-Cell Variant of Papillary Thyroid Cancer: Have We Reached a Consensus?. Thyroid, 2017, 27, 1498-1504.	2.4	32
126	Clinical Applications of Whole-slide Imaging in Anatomic Pathology. Advances in Anatomic Pathology, 2017, 24, 215-221.	2.4	23

#	Article	IF	Citations
127	Malignant Ovarian Steroid Cell Tumor Causing Severe Hyperandrogenism: Case Report And Review Of The Literature. AACE Clinical Case Reports, 2017, 3, e269-e274.	0.4	1
128	Ikaros and its interacting partner CtBP target the metalloprotease ADAMTS10 to modulate pituitary cell function. Molecular and Cellular Endocrinology, 2017, 439, 126-132.	1.6	4
129	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Thyroid Carcinoma. Archives of Pathology and Laboratory Medicine, 2017, 141, 559-563.	1.2	9
130	TFE3-Expressing Perivascular Epithelioid Cell Neoplasm (PEComa) of the Sella Turcica. Endocrine Pathology, 2017, 28, 22-26.	5.2	9
131	Hypothalamic Disease. , 2017, , 97-106.		0
132	FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. Oncotarget, 2017, 8, 3481-3494.	0.8	14
133	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2016, 40, 569-576.	2.1	75
134	Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treatment Reviews, 2016, 47, 32-45.	3.4	74
135	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	3.4	1,192
136	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	7.7	482
137	Inter-Observer Variation in the Pathologic Identification of Extranodal Extension in Nodal Metastasis from Papillary Thyroid Carcinoma. Thyroid, 2016, 26, 816-819.	2.4	12
138	Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft. Endocrine Pathology, 2016, 27, 97-103.	5.2	14
139	Cytology and Pathology: Pitfalls and Challenges. , 2016, , 33-46.		3
140	Synchronous Papillary Carcinoma of Thyroid and Lung. Endocrine Pathology, 2016, 27, 268-270.	5.2	1
141	The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surgery, 2016, 151, 959.	2.2	840
142	Gonadotrope Tumors. Progress in Molecular Biology and Translational Science, 2016, 143, 187-210.	0.9	3
143	NG2 targets tumorigenic Rb inactivation in Pit1-lineage pituitary cells. Endocrine-Related Cancer, 2016, 23, 445-456.	1.6	8
144	Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. European Journal of Endocrinology, 2016, 174, 307-314.	1.9	25

#	Article	IF	Citations
145	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	1.8	179
146	Inter-Observer Variation in the Pathologic Identification of Minimal Extrathyroidal Extension in Papillary Thyroid Carcinoma. Thyroid, 2016, 26, 512-517.	2.4	56
147	Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. Expert Review of Endocrinology and Metabolism, 2016, 11, 149-162.	1.2	42
148	Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Modern Pathology, 2016, 29, 131-142.	2.9	114
149	Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism. Endocrine Pathology, 2016, 27, 25-33.	5.2	26
150	Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. Clinical Cancer Research, 2016, 22, 250-258.	3.2	149
151	High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor. Oncotarget, 2016, 7, 19948-19959.	0.8	15
152	Clinical implications of accurate subtyping of pituitary adenomas: perspectives from the treating physician. Turk Patoloji Dergisi, 2015, 31 Suppl 1, 4-17.	0.1	14
153	Pancreatic Neuroendocrine Tumors Producing GHRH, GH, Ghrelin, PTH, or PTHrP. , 2015, , 125-139.		3
154	Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy. , 2015, , .		8
155	Modeling complexity in pathologist workload measurement: the Automatable Activity-Based Approach to Complexity Unit Scoring (AABACUS). Modern Pathology, 2015, 28, 324-339.	2.9	23
156	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 2015, 25, 567-610.	2.4	1,738
157	Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 727-732.	1.4	38
158	When Thyroid Carcinoma Goes Bad: A Morphological and Molecular Analysis. Head and Neck Pathology, 2015, 9, 16-23.	1.3	50
159	Ultrastructural features of collagen in thyroid carcinoma tissue observed by polarization second harmonic generation microscopy. Biomedical Optics Express, 2015, 6, 3475.	1.5	56
160	The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocrine Pathology, 2015, 26, 349-355.	5.2	167
161	In Reply. Archives of Pathology and Laboratory Medicine, 2015, 139, 967-968.	1.2	0
162	Implications of the TCGA Genomic Characterization of Papillary Thyroid Carcinoma for Thyroid Pathology: Does Follicular Variant Papillary Thyroid Carcinoma Exist?. Thyroid, 2015, 25, 1-2.	2.4	54

#	Article	IF	Citations
163	Targeted expression of a human pituitary tumorâ€“derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation, 2015, 125, 3303-3303.	3.9	1
164	NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. Journal of Clinical Oncology, 2015, 33, 2594-2594.	0.8	4
165	An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140105.	0.2	9
166	Malignant Pheochromocytoma Secreting Vasoactive Intestinal Peptide and Response to Sunitinib: A Case Report and Literature Review. Endocrine Practice, 2014, 20, e145-e150.	1.1	15
167	TTF-1 Expressing Sellar Neoplasm with Ependymal Rosettes and Oncocytic Change: Mixed Ependymal and Oncocytic Variant Pituicytoma. Endocrine Pathology, 2014, 25, 436-438.	5.2	21
168	The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocrine-Related Cancer, 2014, 21, R331-R344.	1.6	61
169	Metastatic Thyroid Carcinoma to the Gastric Body. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3958-3959.	1.8	9
170	Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCCâ€“PGL syndromes: a clinicopathological and molecular analysis. European Journal of Endocrinology, 2014, 170, 1-12.	1.9	219
171	Protocol for the Examination of Specimens From Patients With Pheochromocytomas and Extra-Adrenal Paragangliomas. Archives of Pathology and Laboratory Medicine, 2014, 138, 182-188.	1.2	52
172	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 2014, 159, 676-690.	13.5	2,318
173	Multiple Endocrine Neoplasia Type 1. , 2014, 19, 85-89.		6
174	Editorial: The Birth of Endocrine Pathology. Endocrine Pathology, 2014, 25, 2-2.	5.2	1
175	Functional Cardiac Paraganglioma Associated with a Rare SDHC Mutation. Endocrine Pathology, 2014, 25, 315-320.	5.2	16
176	A History of Pituitary Pathology. Endocrine Pathology, 2014, 25, 6-11.	5.2	3
177	Genomic Approaches to Problems in Pituitary Neoplasia. Endocrine Pathology, 2014, 25, 209-213.	5.2	10
178	FGFR4 Polymorphic Variants Modulate Phenotypic Features of Cushing Disease. Molecular Endocrinology, 2014, 28, 525-533.	3.7	18
179	Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Modern Pathology, 2014, 27, 1050-1062.	2.9	17
180	Genetics and Epigenetics of Endocrine Neoplasia. Molecular and Cellular Endocrinology, 2014, 386, 1.	1.6	1

#	Article	IF	Citations
181	A single-arm, phase II, multicenter trial of sunitinib (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Updated interim results.. Journal of Clinical Oncology, 2014, 32, e15621-e15621.	0.8	0
182	Parathyroid cancer: Outcome analysis of 16 patients treated at the princess margaret hospital. Head and Neck, 2013, 35, 35-39.	0.9	49
183	Silent Corticotroph Adenoma with Adrenal Cortical Choristoma: a Rare but Distinct Morphological Entity. Endocrine Pathology, 2013, 24, 162-166.	5.2	7
184	Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippelâ€“Lindau disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 593-597.	1.4	28
185	Postnatal Ablation of POMC Neurons Induces an Obese Phenotype Characterized by Decreased Food Intake and Enhanced Anxiety-Like Behavior. Molecular Endocrinology, 2013, 27, 1091-1102.	3.7	59
186	Therapeutic implications of accurate classification of pituitary adenomas. Seminars in Diagnostic Pathology, 2013, 30, 158-164.	1.0	48
187	Thyroid neoplasms of follicular cell derivation: A simplified approach. Seminars in Diagnostic Pathology, 2013, 30, 178-185.	1.0	8
188	The Role of Mediators of Cell Invasiveness, Motility, and Migration in the Pathogenesis of Silent Corticotroph Adenomas. Endocrine Pathology, 2013, 24, 191-198.	5.2	30
189	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nature Genetics, 2013, 45, 1483-1486.	9.4	275
190	The evolving landscape of endocrine pathology practice. Seminars in Diagnostic Pathology, 2013, 30, 157.	1.0	1
191	Follicular epithelial dysplasia of the thyroid: morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 557-563.	1.4	49
192	Recurrent Acute-Onset Cushingâ€™s Syndrome 6ÂYears after Removal of a Thymic Neuroendocrine Carcinoma: From Ectopic ACTH to CRH. Endocrine Pathology, 2013, 24, 25-29.	5.2	12
193	The Rationale of Patients with Early-Stage Papillary Thyroid Cancer for Accepting or Rejecting Radioactive Iodine Remnant Ablation. Thyroid, 2013, 23, 246-247.	2.4	9
194	Spindle Cell Oncocytomas and Granular Cell Tumors of the Pituitary Are Variants of Pituicytoma. American Journal of Surgical Pathology, 2013, 37, 1694-1699.	2.1	151
195	Precursor lesions of endocrine system neoplasms. Pathology, 2013, 45, 316-330.	0.3	84
196	Defining diagnostic tissue in the era of personalized medicine. Cmaj, 2013, 185, 135-139.	0.9	17
197	Hormone profiling, WHO 2010 grading, and AJCC / UICC staging in pancreatic neuroendocrine tumor behavior. Cancer Medicine, 2013, 2, 701-711.	1.3	29
198	Metabolic Glucose Status and Pituitary Pathology Portend Therapeutic Outcomes in Acromegaly. PLoS ONE, 2013, 8, e73543.	1.1	11

#	Article	IF	Citations
199	Evaluation of the WHO 2010 Grading and AJCC/UICC Staging Systems in Prognostic Behavior of Intestinal Neuroendocrine Tumors. PLoS ONE, 2013, 8, e61538.	1.1	26
200	Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer. Journal of Clinical Oncology, 2012, 30, 2906-2911.	0.8	40
201	Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in Nonfunctioning Pituitary Adenomas: A High Throughput TMA, Immunohistochemical Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1745-1751.	1.8	123
202	Pitfalls in the Diagnosis of Follicular Epithelial Proliferations of the Thyroid. Advances in Anatomic Pathology, 2012, 19, 363-373.	2.4	32
203	FGFR2 Isoforms Support Epithelialâ€“Stromal Interactions in Thyroid Cancer Progression. Cancer Research, 2012, 72, 2017-2027.	0.4	25
204	Carney Complex with Adrenal Cortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E202-E206.	1.8	57
205	CtBP1 Interacts with Ikaros and Modulates Pituitary Tumor Cell Survival and Response to Hypoxia. Molecular Endocrinology, 2012, 26, 447-457.	3.7	23
206	The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression. Oncogene, 2012, 31, 4012-4021.	2.6	17
207	The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy. Cancer Research, 2012, 72, 5683-5691.	0.4	45
208	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 2012, 22, 1104-1139.	2.4	717
209	Clinical features of silent corticotroph adenomas. Acta Neurochirurgica, 2012, 154, 1493-1498.	0.9	59
210	Biomarkers of aggressive pituitary adenomas. Journal of Molecular Endocrinology, 2012, 49, R69-R78.	1.1	123
211	The Breast Cancer Susceptibility Gene Product Fibroblast Growth Factor Receptor 2 Serves as a Scaffold for Regulation of NF-Î°B Signaling. Molecular and Cellular Biology, 2012, 32, 4662-4673.	1.1	23
212	Images in Endocrine Pathology: Thyrotoxicosis Associated with Destructive Thyroiditis. Endocrine Pathology, 2012, 23, 212-214.	5.2	5
213	Villous Papillary Thyroid Carcinoma: a Variant Associated with Marfan Syndrome. Endocrine Pathology, 2012, 23, 254-259.	5.2	10
214	Biomarkers of Parathyroid Carcinoma. Endocrine Pathology, 2012, 23, 221-231.	5.2	57
215	Prognostic and Predictive Markers in Medullary Thyroid Carcinoma. Endocrine Pathology, 2012, 23, 232-242.	5.2	35
216	Morphological distinction of cortisolâ€producing and aldosteroneâ€producing adrenal cortical adenomas: not only possible but a critical clinical responsibility. Histopathology, 2012, 60, 1015-1016.	1.6	12

#	Article	IF	Citations
217	Clinicopathological Correlations in Pituitary Adenomas. Brain Pathology, 2012, 22, 443-453.	2.1	120
218	XB130, a Novel Adaptor Protein, Promotes Thyroid Tumor Growth. American Journal of Pathology, 2011, 178, 391-401.	1.9	42
219	A Case Report and Review of Hyperprolactinemia that is not Prolactinoma. Canadian Journal of Neurological Sciences, 2011, 38, 652-655.	0.3	3
220	Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative action. Laboratory Investigation, 2011, 91, 147-156.	1.7	14
221	Development of a molecular-beacon-based multi-allelic real-time RT-PCR assay for the detection of human coronavirus causing severe acute respiratory syndrome (SARS-CoV): a general methodology for detecting rapidly mutating viruses. Archives of Virology, 2011, 156, 671-680.	0.9	30
222	Is Adrenal Ovarian Thecal Metaplasia a Misnomer? Report of Three Cases of Radial Scar-Like Spindle Cell Myofibroblastic Nodule of the Adrenal Gland. Endocrine Pathology, 2011, 22, 222-225.	5.2	4
223	Images in Endocrine Pathology: Lipoadenoma-like Cystic Epithelial Lesion in the Lateral Neck. Endocrine Pathology, 2011, 22, 229-231.	5.2	0
224	Sellar Glomangioma. Endocrine Pathology, 2011, 22, 218-221.	5.2	9
225	EWSR1â€ATF1 fusion is a novel and consistent finding in hyalinizing clearâ€cell carcinoma of salivary gland. Genes Chromosomes and Cancer, 2011, 50, 559-570.	1.5	339
226	Molecular pathology of thyroid cancer. Diagnostic Histopathology, 2011, 17, 124-139.	0.2	11
227	Pancreatic endocrine tumors. Modern Pathology, 2011, 24, S66-S77.	2.9	72
228	Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Modern Pathology, 2011, 24, 1545-1552.	2.9	178
229	A High-Throughput Proteomic Approach Provides Distinct Signatures for Thyroid Cancer Behavior. Clinical Cancer Research, 2011, 17, 2385-2394.	3.2	67
230	The FGFR4-G388R Polymorphism Promotes Mitochondrial STAT3 Serine Phosphorylation to Facilitate Pituitary Growth Hormone Cell Tumorigenesis. PLoS Genetics, 2011, 7, e1002400.	1.5	59
231	â€œNext-Generationâ€•Pathology and Laboratory Medicine. Archives of Pathology and Laboratory Medicine, 2011, 135, 1531-1532.	1.2	17
232	Protocol for the Examination of Specimens From Patients With Primary Pituitary Tumors. Archives of Pathology and Laboratory Medicine, 2011, 135, 640-646.	1.2	33
233	Controversies in Thyroid Pathology: Thyroid Capsule Invasion and Extrathyroidal Extension. Annals of Surgical Oncology, 2010, 17, 386-391.	0.7	94
234	Oncocytes, Oxyphils, HÃ¼rthle, and Askanazy Cells: Morphological and Molecular Features Of Oncocytic Thyroid Nodules. Endocrine Pathology, 2010, 21, 16-24.	5.2	65

#	Article	IF	Citations
235	GNAq Mutations are Not Identified in Papillary Thyroid Carcinomas and Hyperfunctioning Thyroid Nodules. Endocrine Pathology, 2010, 21, 250-252.	5.2	3
236	Ectopic Thyroid Tissue Within the Gall Bladder: Case Report and Brief Review of the Literature. Endocrine Pathology, 2010, 21, 263-265.	5.2	41
237	Adenohypophysitis in rat pituitary allografts. International Journal of Experimental Pathology, 2010, 91, 445-450.	0.6	2
238	Adrenal Gland. , 2010, , 461-485.		1
239	Chromatin remodeling and histone modifications in pituitary tumors. Molecular and Cellular Endocrinology, 2010, 326, 66-70.	1.6	20
240	Papillary Thyroid Carcinoma and Variants. , 2010, , 91-116.		6
241	Osteopontin (OPN) expression in thyroid carcinoma. Anticancer Research, 2010, 30, 1681-8.	0.5	18
242	Transcript Level Modulates the Inherent Oncogenicity of RET/PTC Oncoproteins. Cancer Research, 2009, 69, 4861-4869.	0.4	44
243	Histone-Acetylated Control of Fibroblast Growth Factor Receptor 2 Intron 2 Polymorphisms and Isoform Splicing in Breast Cancer. Molecular Endocrinology, 2009, 23, 1397-1405.	3.7	30
244	Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. Endocrine-Related Cancer, 2009, 16, 455-466.	1.6	18
245	Solitary Fibrous Tumor of the Sella Mimicking Pituitary Adenoma: An Uncommon Tumor in a Rare Locationâ€"A Case Report. Endocrine Pathology, 2009, 20, 56-61.	5.2	22
246	Ectopic Growth Hormone-Releasing Hormone Secretion by a Neuroendocrine Tumor Causing Acromegaly: Long-Term Follow-Up Results. Endocrine Pathology, 2009, 20, 127-132.	5.2	10
247	Aldosterone-Producing Adrenal Cortical Adenoma with Oncocytic Change and Cytoplasmic Eosinophilic Globular Inclusions. Endocrine Pathology, 2009, 20, 182-185.	5.2	24
248	Case Report: Adrenal LH/hCG Receptor Overexpression and Gene Amplification Causing Pregnancy-Induced Cushingâ€™s Syndrome. Endocrine Pathology, 2009, 20, 256-261.	5.2	29
249	Osteopontin stimulates invasion of NCIâ€h295 cells but is not associated with survival in adrenocortical carcinoma. Journal of Pathology, 2009, 218, 232-240.	2.1	13
250	Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Modern Pathology, 2009, 22, 431-441.	2.9	120
251	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. Human Pathology, 2009, 40, 1070-1081.	1.1	147
252	The Pathogenesis of Pituitary Tumors. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 97-126.	9.6	225

#	Article	IF	Citations
253	Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 5-9.	1.8	150
254	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. Seminars in Diagnostic Pathology, 2009, 26, 165-176.	1.0	25
255	Composite Medullary and Papillary Thyroid Carcinoma In a Patient With MEN 2B. , 2009, 14, 208-213.		10
256	CEACAM1 Expression in Pancreatic Endocrine Tumors. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 286-293.	0.6	11
257	Pituitary. , 2009, , 1949-1983.		2
258	An unusual association of a sellar gangliocytoma with a prolactinoma. Pituitary, 2008, 11, 85-87.	1.6	33
259	Controversies in Thyroid Pathology: The Diagnosis of Follicular Neoplasms. Endocrine Pathology, 2008, 19, 156-165.	5.2	36
260	Utilization of ancillary studies in thyroid fine needle aspirates: A synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagnostic Cytopathology, 2008, 36, 438-441.	0.5	73
261	Development of a pituitaryâ€specific cre line targeted to the Pitâ€1 lineage. Genesis, 2008, 46, 37-42.	0.8	14
262	Creation of a retrospective searchable neuropathologic database from print archives at Toronto's University Health Network. Laboratory Investigation, 2008, 88, 89-93.	1.7	5
263	Reduction of GSTP1 expression by DNA methylation correlates with clinicopathological features in pituitary adenomas. Modern Pathology, 2008, 21, 856-865.	2.9	26
264	Medullary thyroid carcinoma metastatic to the pituitary gland: an unusual site of metastasis. Annals of Diagnostic Pathology, 2008, 12, 199-203.	0.6	22
265	Mice lacking the transcription factor Ikaros display behavioral alterations of an anti-depressive phenotype. Experimental Neurology, 2008, 211, 107-114.	2.0	16
266	Preface. Endocrinology and Metabolism Clinics of North America, 2008, 37, xvii-xviii.	1.2	3
267	Epigenetic Dysregulation in Thyroid Neoplasia. Endocrinology and Metabolism Clinics of North America, 2008, 37, 389-400.	1.2	26
268	The Melanoma-Associated Antigen A3 Mediates Fibronectin-Controlled Cancer Progression and Metastasis. Cancer Research, 2008, 68, 8104-8112.	0.4	127
269	Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia. Clinical Cancer Research, 2008, 14, 1984-1996.	3.2	70
270	The emerging role of the Ikaros stem cell factor in the neuroendocrine system. Journal of Molecular Endocrinology, 2008, 41, 45-51.	1.1	19

#	Article	IF	Citations
271	Interobserver and Intraobserver Variation Among Experts in the Diagnosis of Thyroid Follicular Lesions With Borderline Nuclear Features of Papillary Carcinoma. American Journal of Clinical Pathology, 2008, 130, 736-744.	0.4	280
272	Ikaros Modulates Cholesterol Uptake: A Link between Tumor Suppression and Differentiation. Cancer Research, 2008, 68, 3715-3723.	0.4	27
273	Pituitary-Specific Knockout of the Carney Complex Gene Prkar1a Leads to Pituitary Tumorigenesis. Molecular Endocrinology, 2008, 22, 380-387.	3.7	73
274	Deoxyribonucleic Acid Methyltransferase 3B Promotes Epigenetic Silencing through Histone 3 Chromatin Modifications in Pituitary Cells. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3610-3617.	1.8	41
275	Loss of Membrane Localization and Aberrant Nuclear E-cadherin Expression Correlates With Invasion in Pancreatic Endocrine Tumors. American Journal of Surgical Pathology, 2008, 32, 413-419.	2.1	66
276	Composite Pituitary Adenoma and Craniopharyngioma?. American Journal of Surgical Pathology, 2008, 32, 1736-1741.	2.1	23
277	New Diagnostic and Management Approaches in Endocrine Pathology. Archives of Pathology and Laboratory Medicine, 2008, 132, 1228-1230.	1.2	1
278	Practical Pituitary Pathology: What Does the Pathologist Need to Know?. Archives of Pathology and Laboratory Medicine, 2008, 132, 1231-1240.	1.2	82
279	Composite Adenomatoid Tumor and Myelolipoma of Adrenal Gland: Report of 2 Cases. Archives of Pathology and Laboratory Medicine, 2008, 132, 265-267.	1.2	21
280	Application of Immunohistochemistry to Thyroid Neoplasms. Archives of Pathology and Laboratory Medicine, 2008, 132, 359-372.	1.2	113
281	Adenohypophysitis in rat pituitary allografts.. FASEB Journal, 2008, 22, .	0.2	0
282	Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer Progression. Cancer Research, 2007, 67, 5461-5470.	0.4	65
283	A Growth Hormone Receptor Mutation Impairs Growth Hormone Autofeedback Signaling in Pituitary Tumors. Cancer Research, 2007, 67, 7505-7511.	0.4	64
284	Ikaros Is Regulated through Multiple Histone Modifications and Deoxyribonucleic Acid Methylation in the Pituitary. Molecular Endocrinology, 2007, 21, 1205-1215.	3.7	19
285	The Cancer/Testis Antigen Melanoma-Associated Antigen-A3/A6 Is a Novel Target of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3 Modifications in Thyroid Cancer. Clinical Cancer Research, 2007, 13, 4713-4720.	3.2	47
286	Familial Pituitary Adenomas and Loss of Function of AIP. Advances in Anatomic Pathology, 2007, 14, 58-59.	2.4	1
287	Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Human Pathology, 2007, 38, 1810-1818.	1.1	40
288	Epigenetic Silencing through DNA and Histone Methylation of Fibroblast Growth Factor Receptor 2 in Neoplastic Pituitary Cells. American Journal of Pathology, 2007, 170, 1618-1628.	1.9	68

#	Article	IF	Citations
289	Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development. European Journal of Immunology, 2007, 37, 2234-2241.	1.6	54
290	CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene, 2007, 26, 2747-2758.	2.6	60
291	Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Modern Pathology, 2007, 20, 1269-1277.	2.9	91
292	Completion Thyroidectomy Versus Total Thyroidectomy: Is There a Difference in Complication Rates? An Analysis of 350 Patients. Journal of the American College of Surgeons, 2007, 205, 602-607.	0.2	85
293	Complex Endocrinopathies in MEN-1: Diagnostic Dilemmas in Endocrine Oncology. Endocrine Pathology, 2007, 18, 37-41.	5.2	14
294	AIP Mutations are not Identified in Patients with Sporadic Pituitary Adenomas. Endocrine Pathology, 2007, 18, 76-78.	5.2	32
295	Myelolipoma with Adrenocortical Adenoma: An unusual Combination that can Resemble Carcinoma. Endocrine Pathology, 2007, 18, 103-105.	5.2	10
296	Follicular Variant Papillary Thyroid Carcinoma Arising in Struma Ovarii. Endocrine Pathology, 2007, 18, 182-186.	5.2	54
297	Creation of a Retrospective Searchable Neuropathologic Database from Print Archives: The UHN Experience. FASEB Journal, 2007, 21, A400.	0.2	0
298	Mechanisms of Disease: the pathogenesis of pituitary tumors. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 220-230.	2.9	85
299	Cellâ€“cell communication in the pituitary: orchestrator of pulsatile growth hormone secretion?. Trends in Endocrinology and Metabolism, 2006, 17, 299-300.	3.1	10
300	Pancreatic endocrine tumour with ductules: further observations of an unusual histological subtype. Pathology, 2006, 38, 5-9.	0.3	7
301	The Predictive Value of CK19 and CD99 in Pancreatic Endocrine Tumors. American Journal of Surgical Pathology, 2006, 30, 1588-1594.	2.1	61
302	Microadenomatosis of the Pancreas in von Hippel-Lindau Disease. American Journal of Surgical Pathology, 2006, 30, 1630.	2.1	9
303	Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer, 2006, 6, 292-306.	12.8	797
304	Intracytoplasmic Inclusions (Including the So-Called "Rhabdoid" Phenotype) in Pancreatic Endocrine Tumors. Endocrine Pathology, 2006, 17, 75-82.	5.2	17
305	Plurihormonality in Pituitary Adenomas Associated with Acromegaly. Endocrine Pathology, 2006, 17, 291-296.	5.2	13
306	The 2004 World Health Organization classification of pituitary tumors: What is new?. Acta Neuropathologica, 2006, 111, 1-7.	3.9	121

#	Article	IF	Citations
307	Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer, 2006, 107, 1786-1792.	2.0	105
308	Cushing's Syndrome Due to Ectopic CRH Secretion by Adrenal Pheochromocytoma Accompanied by Renal Infarction. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 444-447.	0.6	35
309	Tumor-Derived Ikaros 6 Acetylates the Bcl-XL Promoter to Up-Regulate a Survival Signal in Pituitary Cells. Molecular Endocrinology, 2006, 20, 2976-2986.	3.7	41
310	Ependymoma of the pituitary fossa. Journal of Neurosurgery, 2006, 105, 616-620.	0.9	16
311	Acromegaly and Somatotroph Hyperplasia with Adenomatous Transformation Due to Pituitary Metastasis of a Growth Hormone-Releasing Hormone-Secreting Pulmonary Endocrine Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4776-4780.	1.8	49
312	An essential role for the hematopoietic transcription factor Ikaros in hypothalamicâ€“pituitary-mediated somatic growth. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2214-2219.	3.3	44
313	Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications. Molecular Endocrinology, 2006, 20, 2965-2975.	3.7	49
314	Dopaminergic Resistant Prolactinomas in the Peripubertal Population. Journal of Pediatric Endocrinology and Metabolism, 2006, 19, 951-3.	0.4	12
315	Papillary Thyroid Carcinoma: An Overview. Archives of Pathology and Laboratory Medicine, 2006, 130, 1057-1062.	1.2	65
316	Pancreatic Endocrine Tumors With Ductules. American Journal of Surgical Pathology, 2005, 29, 136-137.	2.1	3
317	Genetics and Proteomics of Pituitary Tumors. Endocrine, 2005, 28, 043-048.	2.2	38
318	Angiopoietins Are Expressed in the Normal Rat Pituitary Gland. Endocrine Pathology, 2005, 16, 067-074.	5.2	5
319	Double Adenomas of the Pituitary: Transcription Factors Pit-1, T-pit, and SF-1 Identify Cytogenesis and Differentiation. Endocrine Pathology, 2005, 16, 187-194.	5.2	40
320	The Role of Immunohistochemical Markers in the Diagnosis of Follicular-Patterned Lesions of the Thyroid. Endocrine Pathology, 2005, 16, 295-310.	5.2	59
321	Left Atrial Myxoma Presenting as Migraine With Aura: A VIPâ€induced Syndrome?. Headache, 2005, 45, 251-254.	1.8	9
322	Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Laboratory Investigation, 2005, 85, 464-473.	1.7	47
323	Pulmonary pathology of severe acute respiratory syndrome in Toronto. Modern Pathology, 2005, 18, 1-10.	2.9	331
324	Anaplastic Carcinoma of the Thyroid Gland. , 2005, , 159-167.		5

#	Article	IF	Citations
325	FGF Receptor Signaling at the Crossroads of Endocrine Homeostasis and Tumorigenesis. Hormone and Metabolic Research, 2005, 37, 355-360.	0.7	23
326	Fibroblast Growth Factor Receptors as Molecular Targets in Thyroid Carcinoma. Endocrinology, 2005, 146, 1145-1153.	1.4	115
327	The Zinc Finger Ikaros Transcription Factor Regulates Pituitary Growth Hormone and Prolactin Gene Expression through Distinct Effects on Chromatin Accessibility. Molecular Endocrinology, 2005, 19, 1004-1011.	3.7	40
328	The Implication of Somatotroph Adenoma Phenotype to Somatostatin Analog Responsiveness in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6290-6295.	1.8	165
329	1Î±,25-Dihydroxyvitamin D3 Targets PTEN-Dependent Fibronectin Expression to Restore Thyroid Cancer Cell Adhesiveness. Molecular Endocrinology, 2005, 19, 2349-2357.	3.7	46
330	Gonadotroph Tumor Associated with Multiple Endocrine Neoplasia Type 1. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 570-574.	1.8	40
331	The Pathology of Thyroid Cancer. Cancer Treatment and Research, 2005, 122, 23-68.	0.2	5
332	Fatal Severe Acute Respiratory Syndrome Is Associated with Multiorgan Involvement by Coronavirus. Journal of Infectious Diseases, 2005, 191, 193-197.	1.9	153
333	Ikaros integrates endocrine and immune system development. Journal of Clinical Investigation, 2005, 115, 1021-1029.	3.9	39
334	Rhabdoid Tumor of the Thyroid Gland: A Variant of Anaplastic Carcinoma. Archives of Pathology and Laboratory Medicine, 2005, 129, e55-e57.	1.2	30
335	Ikaros integrates endocrine and immune system development. Journal of Clinical Investigation, 2005, 115, 1021-1029.	3.9	35
336	Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clinical Cancer Research, 2005, 11, 1336-41.	3.2	57
337	Expression of nm23 antimetastatic gene product in parathyroid hyperplasia, adenoma and carcinoma. An immunohistological assessment. Journal of King Abdulaziz University, Islamic Economics, 2005, 26, 728-31.	0.5	1
338	Severe Acute Respiratory Syndromeâ€“associated Coronavirus in Lung Tissue. Emerging Infectious Diseases, 2004, 10, 20-24.	2.0	61
339	Hypothalamic Disease. , 2004, , 678-687.		0
340	Vitamin D3 Administration Induces Nuclear p27 Accumulation, Restores Differentiation, and Reduces Tumor Burden in a Mouse Model of Metastatic Follicular Thyroid Cancer. Endocrinology, 2004, 145, 5840-5846.	1.4	58
341	Hyalinizing Trabecular Tumor of the Thyroid Gland. American Journal of Clinical Pathology, 2004, 122, 495-496.	0.4	18
342	Pituitary Tumor-Derived Fibroblast Growth Factor Receptor 4 Isoform Disrupts Neural Cell-Adhesion Molecule/N-Cadherin Signaling to Diminish Cell Adhesiveness: A Mechanism Underlying Pituitary Neoplasia. Molecular Endocrinology, 2004, 18, 2543-2552.	3.7	86

#	Article	IF	Citations
343	Sp1-Mediated Transcriptional Control of Fibroblast Growth Factor Receptor 4 in Sarcomas of Skeletal Muscle Lineage. Clinical Cancer Research, 2004, 10, 6750-6758.	3.2	19
344	Distinct transcriptional control and action of fibroblast growth factor receptor 4 in differentiating skeletal muscle cells. Laboratory Investigation, 2004, 84, 1571-1580.	1.7	14
345	Pancreatic Endocrine Pathology in von Hippelâ€“Lindau Disease: An Expanding Spectrum of Lesions. Endocrine Pathology, 2004, 15, 141-148.	5.2	48
346	Granulomatous Hypophysitis with Psammoma Bodies: A Diagnostic Dilemma. Endocrine Pathology, 2004, 15, 359-364.	5.2	7
347	The prevalence of pituitary adenomas. Cancer, 2004, 101, 613-619.	2.0	1,126
348	Cytoplasmic Expression of Fibroblast Growth Factor Receptor-4 in Human Pituitary Adenomas: Relation to Tumor Type, Size, Proliferation, and Invasiveness. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1904-1911.	1.8	72
349	Molecular Basis of Pituitary Development and Cytogenesis. , 2004, 32, 1-19.		42
350	Pancreatic Endocrine Tumors. Advances in Anatomic Pathology, 2004, 11, 202-210.	2.4	19
351	Observer Variation in the Diagnosis of Follicular Variant of Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2004, 28, 1336-1340.	2.1	456
352	Current views on pathogenesis of pituitary tumors. Current Opinion in Endocrinology, Diabetes and Obesity, 2004, 11, 281-286.	0.6	0
353	Ductules in Pancreatic Neuroendocrine Tumors. American Journal of Surgical Pathology, 2004, 28, 417.	2.1	2
354	Hyalinizing trabecular tumor of the thyroid gland: much ado about nothing?. American Journal of Clinical Pathology, 2004, 122, 495-6.	0.4	7
355	"Honeycomb Golgi" in Pituitary Adenomas: Not a Marker of Gonadotroph Adenomas. Endocrine Pathology, 2003, 14, 363-368.	5.2	16
356	Controversies in papillary microcarcinoma of the thyroid. Endocrine Pathology, 2003, 14, 183-191.	5.2	73
357	Genetic abnormalities of the endothelium. Microscopy Research and Technique, 2003, 60, 30-37.	1.2	8
358	Myostatin Is a Skeletal Muscle Target of Growth Hormone Anabolic Action. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5490-5496.	1.8	120
359	Ikaros Isoforms in Human Pituitary Tumors. American Journal of Pathology, 2003, 163, 1177-1184.	1.9	78
360	Malignant Teratoma of the Thyroid: Aggressive Chemoradiation Therapy is Required After Surgery. Thyroid, 2003, 13, 401-404.	2.4	30

#	Article	IF	Citations
361	Pituitary Tumor AP-2Î± Recognizes a Cryptic Promoter in Intron 4 of Fibroblast Growth Factor Receptor 4. Journal of Biological Chemistry, 2003, 278, 19597-19602.	1.6	45
362	Intratumoral Lymphatics and Lymph Node Metastases in Papillary Thyroid Carcinoma. JAMA Otolaryngology, 2003, 129, 716.	1.5	93
363	Management of Lesions of the Pituitary Stalk and Hypothalamus. , 2003, 13, 38-51.		16
364	Parathyroid Pathology: A Practical Approach. , 2003, 8, 34-41.		1
365	Pseudopheochromocytoma of Pregnancy. Endocrine Practice, 2003, 9, 376-379.	1.1	10
366	Controversies in Papillary Microcarcinoma of the Thyroid. Endocrine Pathology, 2003, 14, 183-192.	5.2	12
367	Expression of p53 in Inverted Papilloma and Malignancy Associated with Inverted Papilloma. The Journal of Otolaryngology, 2003, 32, 048.	0.6	13
368	Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Research, 2003, 63, 3716-23.	0.4	67
369	Ectopic ACTH Syndrome: Discrepancy between Somatostatin Receptor Status in vivo and ex vivo, and between Immunostaining and Gene Transcription for POMC and CRH. Hormone Research in Paediatrics, 2002, 57, 200-204.	0.8	29
370	Underexpression of p27/Kip in Thyroid Papillary Microcarcinomas With Gross Metastatic Disease. JAMA Otolaryngology, 2002, 128, 253.	1.5	58
371	Overexpression of Cyclin D1 and Underexpression of p27 Predict Lymph Node Metastases in Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1814-1818.	1.8	126
372	Cyclin D1 Protein Expression Predicts Metastatic Behavior in Thyroid Papillary Microcarcinomas But Is Not Associated with Gene Amplification. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1810-1813.	1.8	86
373	Pituitary, Pancreatic and Gut Neuroendocrine Defects in Protein Tyrosine Phosphatase-Sigma-Deficient Mice. Molecular Endocrinology, 2002, 16, 155-169.	3.7	31
374	Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary. Molecular Endocrinology, 2002, 16, 1069-1078.	3.7	40
375	Growth Enhancement in Suppressor of Cytokine Signaling 2 (SOCS-2)-Deficient Mice Is Dependent on Signal Transducer and Activator of Transcription 5b (STAT5b). Molecular Endocrinology, 2002, 16, 1394-1406.	3.7	145
376	Prolonged Gastrointestinal Transit in a Patient with a Glucagon-Like Peptide (GLP)-1- and -2-Producing Neuroendocrine Tumor. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3078-3083.	1.8	34
377	Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E490-E495.	1.8	12
378	HÃ¼rthle Cell Tumors. JAMA Otolaryngology, 2002, 128, 237.	1.5	48

#	Article	IF	Citations
379	Vitamin D Arrests Thyroid Carcinoma Cell Growth and Induces p27 Dephosphorylation and Accumulation through PTEN/Akt-Dependent and -Independent Pathways. American Journal of Pathology, 2002, 160, 511-519.	1.9	80
380	Thyroid calcification and its association with thyroid carcinoma. Head and Neck, 2002, 24, 651-655.	0.9	204
381	Correlation of biochemical parameters with single parathyroid adenoma weight and volume. Head and Neck, 2002, 24, 1000-1003.	0.9	56
382	The pathogenesis of pituitary tumours. Nature Reviews Cancer, 2002, 2, 836-849.	12.8	327
383	Medical management of pituitary adenomas: structural and ultrastructural changes. Pituitary, 2002, 5, 133-139.	1.6	16
384	Pituitary Adenoma with "Honeycomb Golgi" Appearance Showing a Phenotypic Change at Recurrence from Clinically Nonfunctioning to Typical Cushing Disease. Endocrine Pathology, 2002, 13, 125-130.	5.2	21
385	Thyroid Gland: International Case Conference. Endocrine Pathology, 2002, 13, 131-134.	5.2	27
386	Prediction of Malignant Behavior of Pheochromocytomas and Paragangliomas Using Immunohistochemical Techniques. Endocrine Pathology, 2002, 13, 149-156.	5.2	41
387	Is Granulomatous Thyroiditis a Complication of Breast Implants?. Endocrine Pathology, 2002, 13, 239-244.	5.2	10
388	Vitamin D and Its Analog EB1089 Induce p27 Accumulation and Diminish Association of p27 with Skp2 Independent of PTEN in Pituitary Corticotroph Cells. Brain Pathology, 2002, 12, 412-419.	2.1	34
389	Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. Journal of Clinical Investigation, 2002, 110, 973-981.	3.9	95
390	Targeted expression of a human pituitary tumorâ€“derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation, 2002, 109, 69-78.	3.9	155
391	Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. Journal of Clinical Investigation, 2002, 110, 973-981.	3.9	56
392	Genetic Events in the Evolution of Thyroid Cancer. The Journal of Otolaryngology, 2002, 31, 202.	0.6	8
393	Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma. Modern Pathology, 2001, 14, 338-342.	2.9	298
394	A Soluble Dominant Negative Fibroblast Growth Factor Receptor 4 Isoform in Human MCF-7 Breast Cancer Cells. Biochemical and Biophysical Research Communications, 2001, 287, 60-65.	1.0	35
395	RET Oncogene Activation in Papillary Thyroid Carcinoma. Advances in Anatomic Pathology, 2001, 8, 345-354.	2.4	205
396	The Mindâ€™s Eye. American Journal of Clinical Pathology, 2001, 116, 635-636.	0.4	10

#	Article	IF	Citations
397	Growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) isoform expression in ectopic acromegaly. Clinical Endocrinology, 2001, 55, 135-140.	1.2	23
398	Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma. Clinical Endocrinology, 2001, 55, 549-556.	1.2	43
399	Isolation of a Murine Homologue of the Drosophila neuralized Gene, a Gene Required for Axonemal Integrity in Spermatozoa and Terminal Maturation of the Mammary Gland. Molecular and Cellular Biology, 2001, 21, 7481-7494.	1.1	50
400	Stage-Sensitive Blockade of Pituitary Somatomammotrope Development by Targeted Expression of a Dominant Negative Epidermal Growth Factor Receptor in Transgenic Mice. Molecular Endocrinology, 2001, 15, 600-613.	3.7	45
401	The Pathophysiology of Pituitary Tumors. Seminars in Neurosurgery, 2001, 12, 261-272.	0.0	0
402	The Classification of Pituitary Tumors: An Update. Seminars in Neurosurgery, 2001, 12, 273-288.	0.0	1
403	Growth Hormone Deficiency and Physical Function. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1839-1846.	1.8	1
404	The Endogenous Fibroblast Growth Factor-2 Antisense Gene Product Regulates Pituitary Cell Growth and Hormone Production. Molecular Endocrinology, 2001, 15, 589-599.	3.7	54
405	Analysis of ret/PTC Gene Rearrangements Refines the Fine Needle Aspiration Diagnosis of Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2187-2190.	1.8	169
406	The Spectrum and Significance of Primary Hypophysitis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1048-1053.	1.8	182
407	How Familial Cancer Genes and Environmentally Induced Oncogenes Have Changed the Endocrine Landscape. Modern Pathology, 2001, 14, 246-253.	2.9	17
408	Conclusion. Modern Pathology, 2001, 14, 261-262.	2.9	1
409	Transgenic and Knockout Mouse Models Clarify Pituitary Development, Function and Disease. Brain Pathology, 2001, 11, 370-383.	2.1	10
410	Papillary Carcinoma of Thyroid Metastatic to the Pituitary Gland. Archives of Pathology and Laboratory Medicine, 2001, 125, 935-938.	1.2	45
411	FISHing in the thyroid: new gene rearrangements and new ideas about their pathophysiologic basis. Advances in Anatomic Pathology, 2001, 8, 359-360.	2.4	0
412	Hyalinizing Trabecular Tumor of the Thyroid: A Variant of Papillary Carcinoma Proved By Molecular Genetics. American Journal of Surgical Pathology, 2000, 24, 1622-1626.	2.1	153
413	Human skin expresses growth hormone but not the prolactin gene. Translational Research, 2000, 136, 476-481.	2.4	43
414	Neuroendocrine Function and Response to Stress in Mice with Complete Disruption of Glucagon-Like Peptide-1 Receptor Signaling1. Endocrinology, 2000, 141, 752-762.	1.4	111

#	Article	IF	Citations
415	Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 878-882.	1.8	111
416	Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. Journal of Endocrinology, 2000, 167, 417-428.	1.2	149
417	Evidence for Growth Hormone (GH) Autoregulation in Pituitary Somatotrophs in GH Antagonist-Transgenic Mice and GH Receptor-Deficient Mice. American Journal of Pathology, 2000, 156, 1009-1015.	1.9	61
418	Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. Clinica Chimica Acta, 2000, 300, 171-180.	0.5	18
419	Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 878-882.	1.8	89
420	Cystic Lesions of the Pituitary: Clinicopathological Features Distinguishing Craniopharyngioma, Rathkeâ€™s Cleft Cyst, and Arachnoid Cyst. Obstetrical and Gynecological Survey, 2000, 55, 221-223.	0.2	0
421	Measures of Submaximal Aerobic Performance Evaluate and Predict Functional Response to Growth Hormone (GH) Treatment in GH-Deficient Adults1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4570-4577.	1.8	94
422	Essential Requirement forPax6 in Control of Enteroendocrine Proglucagon Gene Transcription. Molecular Endocrinology, 1999, 13, 1474-1486.	3.7	105
423	Cystic Lesions of the Pituitary: Clinicopathological Features Distinguishing Craniopharyngioma, Rathkeâ€™s Cleft Cyst, and Arachnoid Cyst. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3972-3982.	1.8	221
424	Pituitary Lactotroph Adenomas Develop after Prolonged Lactotroph Hyperplasia in Dopamine D2 Receptor-Deficient Mice1. Endocrinology, 1999, 140, 5348-5355.	1.4	159
425	Pit-1 Binding Sites at the Somatotrope-specific DNase I Hypersensitive Sites I, II of the Human Growth Hormone Locus Control Region Are Essential for in Vivo hGH-N Gene Activation. Journal of Biological Chemistry, 1999, 274, 35725-35733.	1.6	68
426	Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament .. Clinical Endocrinology, 1999, 51, 671-671.	1.2	3
427	Limbic Seizures Alter Reproductive Function in the Female Rat. Epilepsia, 1999, 40, 1370-1377.	2.6	72
428	Molecular determinants of pituitary cytodifferentiation. , 1999, 1, 159-168.		46
429	Clinicopathological variations in cushingâ€™s syndrome. Endocrine Pathology, 1999, 10, 165-171.	5.2	2
430	Oncogene profile of papillary thyroid carcinoma. Surgery, 1999, 125, 46-52.	1.0	86
431	THE PATHOLOGY OF PITUITARY TUMORS. Endocrinology and Metabolism Clinics of North America, 1999, 28, 13-43.	1.2	35
432	Familial Adenomatous Polyposis-Associated Thyroid Cancer. American Journal of Pathology, 1999, 154, 127-135.	1.9	150

#	Article	IF	Citations
433	Cytoplasmic staining oferbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. Clinical Endocrinology, 1998, 49, 629-637.	1.2	20
434	Simian Virus 40 T Antigen-Induced Gonadotroph Adenomas: A Model of Human Null Cell Adenomas¹. Endocrinology, 1998, 139, 3342-3351.	1.4	32
435	TheMEN-1Gene Is Rarely Down-Regulated in Pituitary Adenomas1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3210-3212.	1.8	64
436	Nutrient and Peptide Regulation of Somatostatin-28 Secretion from Intestinal Cultures¹. Endocrinology, 1998, 139, 148-155.	1.4	10
437	Distinct MultipleRET/PTC Gene Rearrangements in Multifocal Papillary Thyroid Neoplasia¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4116-4122.	1.8	242
438	The Cytogenesis and Pathogenesis of Pituitary Adenomas*. Endocrine Reviews, 1998, 19, 798-827.	8.9	285
439	DNase I-hypersensitive sites I and II of the human growth hormone locus control region are a major developmental activator of somatotrope gene expression. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10655-10660.	3.3	62
440	Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14938-14943.	3.3	504
441	The MEN-1 Gene Is Rarely Down-Regulated in Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3210-3212.	1.8	50
442	Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1160-1166.	1.8	116
443	Epression of the Apoptosis-Inducing FAS Ligand (FASL) in Human First and Third Trimester Placenta and Choriocarcinoma Cells. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3173-3175.	1.8	88
444	Pituitary Morphology in Anencephalic Human Fetuses. Neuroendocrinology, 1997, 65, 164-172.	1.2	40
445	C-Cell Lesions of the Thyroid. , 1997, 2, 210-217.		7
446	Pituitary Lactotroph Hyperplasia and Chronic Hyperprolactinemia in Dopamine D2 Receptor-Deficient Mice. Neuron, 1997, 19, 103-113.	3.8	398
447	ref/PTC-1, -2, and -3 Oncogene Rearrangements in Human Thyroid Carcinomas: Implications for Metastatic Potential?. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1306-a-1307.	1.8	18
448	Prognostic Features in Tall Cell Papillary Carcinoma and Insular Thyroid Carcinoma. Laryngoscope, 1997, 107, 254-259.	1.1	63
449	Immunohistochemical localization of p53 in human thyroid neoplasms: Correlation with biological behavior. Endocrine Pathology, 1997, 8, 21-28.	5.2	44
450	The câ€•erb Bâ€2/ neu protoâ€•oncogene in human pituitary tumours. Clinical Endocrinology, 1997, 46, 599-606.	1.2	41

#	Article	IF	Citations
451	ret/PTC-1, -2, and -3 Oncogene Rearrangements in Human Thyroid Carcinomas: Implications for Metastatic Potential?. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1306-1306.	1.8	17
452	Papillary Carcinoma of the Thyroid with Stromal Lymphoid Infiltrate. American Journal of Surgical Pathology, 1997, 21, 738-739.	2.1	0
453	Prevalence of Activating ras Mutations in Morphologically Characterized Thyroid Nodules. Thyroid, 1996, 6, 409-416.	2.4	103
454	The Ontogeny of Pit-1 Expression in the Human Fetal Pituitary Gland. Neuroendocrinology, 1996, 63, 349-355.	1.2	24
455	Induction of intestinal epithelial proliferation by glucagon-like peptide 2.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7911-7916.	3.3	777
456	Molecular interactions during pregnancy. Molecular Human Reproduction, 1996, 2, 457-461.	1.3	27
457	Concurrent Medullary and Papillary Carcinomas of Thyroid with Lymph Node Metastases. American Journal of Surgical Pathology, 1996, 20, 245-250.	2.1	78
458	Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 656-662.	1.8	95
459	The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2165-2170.	1.8	89
460	Decreased follistatin gene expression in gonadotroph adenomas. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 3397-3403.	1.8	24
461	â€œWarthin-like Tumorâ€•of the Thyroid. American Journal of Surgical Pathology, 1995, 19, 810-814.	2.1	162
462	Clonality of Thyroid Nodules in Sporadic Goiter. Diagnostic Molecular Pathology, 1995, 4, 113-121.	2.1	113
463	A serum-free system for primary cultures of human pituitary adenomas. Endocrine Pathology, 1995, 6, 289-299.	5.2	5
464	Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas. Endocrine Pathology, 1995, 6, 125-134.	5.2	60
465	HLA-D antigen expression and Langerhans' cell infiltrates in thyroid tumors. Endocrine Pathology, 1995, 6, 197-206.	5.2	3
466	Heat-shock stress-response proteins in endocrine pathology. Endocrine Pathology, 1995, 6, 3-11.	5.2	0
467	Gangliocytomas of the sellar region â€” a review. Experimental and Clinical Endocrinology and Diabetes, 1995, 103, 129-149.	0.6	78
468	The Cloning and Chromosomal Mapping of Two Novel Human Opioid-Somatostatin-like Receptor Genes, GPR7 and GPR8, Expressed in Discrete Areas of the Brain. Genomics, 1995, 28, 84-91.	1.3	122

#	Article	IF	Citations
469	Expression of Growth Factors and Growth Factor Receptors in Normal and Tumorous Human Thyroid Tissues. Thyroid, 1995, 5, 67-73.	2.4	102
470	Management considerations in HÃ¼rthle cell carcinoma. Surgery, 1995, 118, 711-715.	1.0	50
471	Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia?. Life Sciences, 1995, 56, 1523-1527.	2.0	69
472	Diseases of the Pituitary. Neurosurgery Clinics of North America, 1994, 5, 71-95.	0.8	8
473	The Demise of Follicular Carcinoma of the Thyroid Gland. Thyroid, 1994, 4, 233-236.	2.4	192
474	Cerebral and cerebellar gangliocytomas: a morphological study of nine cases. Acta Neuropathologica, 1994, 88, 246-251.	3.9	33
475	The first four years of endocrine pathology. Endocrine Pathology, 1994, 5, 79-80.	5.2	0
476	Thyroid lymphomas in human thyroid tissue with autoimmune thyroid disease xenografted in severe combined immunodeficient mice. Endocrine Pathology, 1994, 5, 169-177.	5.2	0
477	Editorial announcement. Endocrine Pathology, 1994, 5, 197-197.	5.2	0
478	A composite somatotroph-corticotroph pituitary adenoma. Endocrine Pathology, 1994, 5, 240-246.	5.2	17
479	Intrathyroidal lymphoepithelial cysts of probable branchial origin. Human Pathology, 1994, 25, 1238-1242.	1.1	53
480	Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 555-560.	1.8	54
481	Expression of activin/inhibin subunit messenger ribonucleic acids by gonadotroph adenomas. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1399-1403.	1.8	25
482	Endocrine-Immune Interactions in Pituitary Pathology. , 1994, , 243-252.		0
483	Short-term morphologic and functional effects of bromocriptine on pituitary prolactin cell adenomas in vitro. Endocrine Pathology, 1993, 4, 79-85.	5.2	0
484	Immunohistochemical study of p53 protein in human and animal pituitary tumors. Endocrine Pathology, 1993, 4, 95-99.	5.2	45
485	Plurihormonal pituitary tumors: Beyond the one cell-one hormone theory. Endocrine Pathology, 1993, 4, 1-3.	5.2	7
486	The endocrine pancreas and its tumors. Endocrine Pathology, 1993, 4, 120-130.	5.2	8

#	Article	IF	Citations
487	The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma; evidence for dedifferentiation in tumor progression. Endocrine Pathology, 1993, 4, 215-221.	5.2	37
488	Pancreatic xanthomatous neuropathy associated with hyperlipidemia: A cause of abdominal pain mimicking chronic pancreatitis. Human Pathology, 1993, 24, 1023-1025.	1.1	3
489	Clinical Significance of In Situ Hybridization. Experimental and Clinical Endocrinology and Diabetes, 1993, 101, 46-52.	0.6	1
490	Production of alpha-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro. European Journal of Endocrinology, 1993, 129, 565-572.	1.9	18
491	Clinically Non-Functioning Human Pituitary Adenomas. Canadian Journal of Neurological Sciences, 1992, 19, 228-235.	0.3	44
492	Transforming growth factor-Î± in normal and neoplastic human endocrine tissues. Human Pathology, 1992, 23, 1360-1365.	1.1	58
493	Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. Human Pathology, 1992, 23, 884-887.	1.1	33
494	Pituitary Pathology in Acromegaly. Endocrinology and Metabolism Clinics of North America, 1992, 21, 553-574.	1.2	14
495	Histological, immunohistochemical, and ultrastructural features of a rat medullary thyroid carcinoma transfected with a corticotropin-releasing hormone cDNA expression vector. Endocrine Pathology, 1992, 3, 39-46.	5.2	1
496	Silent corticotroph adenoma with multiple cysts: Pars intermedia tumor?. Endocrine Pathology, 1992, 3, 47-51.	5.2	4
497	Hashimotoâ€™s thyroiditis with granulomas: A unifying immunological etiology?. Endocrine Pathology, 1992, 3, 52-57.	5.2	6
498	Absence of somatotrophs, lactotrophs, and thyrotrophs in the pituitary of two dwarfs with hypothyroidism: Deficiency of pituitary transcription factor-1?. Endocrine Pathology, 1992, 3, 93-98.	5.2	1
499	Granulomatous and lymphocytic thyroiditis associated with a follicular adenoma. Endocrine Pathology, 1992, 3, 105-109.	5.2	4
500	Immunohistochemical localization of metal binding proteins in thyroid tissues and tumors. Endocrine Pathology, 1992, 3, 182-187.	5.2	3
501	Utilization of electron microscopic techniques in the in vitro study of adenohypophysial function and regulation. Microscopy Research and Technique, 1992, 20, 136-151.	1.2	2
502	Human Fetal Adenohypophysis: Morphologic and Functional Analysis in vitro. Neuroendocrinology, 1991, 53, 562-572.	1.2	55
503	Changes in hormone production of a recurrent silent corticotroph adenoma of the pituitary: A histologic, immunohistochemical, ultrastructural, and tissue culture study. Human Pathology, 1991, 22, 719-721.	1.1	22
504	Cytogenesis of nonfunctioning pituitary adenomas. Endocrine Pathology, 1991, 2, 177-179.	5.2	3

#	Article	IF	Citations
505	Pituitary corticotroph adenoma with crookeâ€™s hyalinization. Endocrine Pathology, 1991, 2, 111-116.	5.2	17
506	Islet Cell and Extrapancreatic Expression of the LIM Domain Homeobox Geneisl-1. Molecular Endocrinology, 1991, 5, 1633-1641.	3.7	76
507	Regulation of Peptide-YY Synthesis and Secretion in Fetal Rat Intestinal Cultures*. Endocrinology, 1991, 129, 3351-3358.	1.4	29
508	Why? What? Where?. Endocrine Pathology, 1990, 1, 1-3.	5.2	2
509	The adrenal cortex in ectopic adrenocorticotropic hormone syndrome: A morphological study with histology, transmission and scanning electron microscopy, flow cytometry, and image analysis. Endocrine Pathology, 1990, 1, 183-191.	5.2	4
510	Effects of somatostatin on somatotroph adenomas of the human pituitary: An in vitro functional and morphological study. Endocrine Pathology, 1990, 1, 228-235.	5.2	18
511	Thyroid thymoma in childhood. Endocrine Pathology, 1990, 1, 123-127.	5.2	23
512	Immunoreactive luteinizing hormone in functioning corticotroph adenomas of the pituitary. Virchows Archiv A, Pathological Anatomy and Histopathology, 1990, 417, 361-367.	1.4	22
513	Human Pituitary Corticotroph Adenomas in vitro: Morphologic and Functional Responses to Corticotropin-Releasing Hormone and Cortisol. Neuroendocrinology, 1990, 51, 241-248.	1.2	13
514	Intermediate Filaments in the Human Pituitary Gland: An Immunohistochemical Study. Canadian Journal of Neurological Sciences, 1990, 17, 131-136.	0.3	21
515	Glucagon and Related Peptides in Fetal Rat Hypothalamusin Vivoandin Vitro*. Endocrinology, 1990, 126, 110-117.	1.4	43
516	Pituitary Mammosomatotroph Adenomas Develop in Old Mice Transgenic for Growth Hormone-Releasing Hormone. Experimental Biology and Medicine, 1990, 193, 232-235.	1.1	60
517	Parathyroid Hormone-Like Peptide in Normal and Neoplastic Human Endocrine Tissues*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 1112-1118.	1.8	157
518	Gigantism Due to Pituitary Mammosomatotroph Hyperplasia. New England Journal of Medicine, 1990, 323, 322-327.	13.9	77
519	Analysis of Hormone Secretion by Clinically Nonfunctioning Human Pituitary Adenomas Using the Reverse Hemolytic Plaque Assay*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 73-80.	1.8	76
520	Adenohypophysial Changes in Mice Transgenic for Human Growth Hormone-Releasing Factor: A Histological, Immunocytochemical, and Electron Microscopic Investigation*. Endocrinology, 1989, 125, 2710-2718.	1.4	101
521	INTRASELLAR GANGLIOCYTOMA CONTAINING GASTRIN AND GROWTH HORMONEâ€RELEASING HORMONE ASSOCIATED WITH A GROWTH HORMONEâ€SECRETING PITUITARY ADENOMA. Clinical Endocrinology, 1989, 30, 213-224.	1.2	56
522	Pituitary cells producing more than one hormone human pituitary adenomas. Trends in Endocrinology and Metabolism, 1989, 1, 104-107.	3.1	52

#	Article	IF	Citations
523	Effects of growth hormone-releasing hormone (GHRH) on densely granulated somatotroph adenomas and sparsely granulated somatotroph adenomas in vitro: a morphological and functional investigation. Journal of Endocrinological Investigation, 1989, 12, 443-448.	1.8	20
524	Reversible sellar enlargement due to growth hormone-releasing hormone production by pancreatic endocrine tumors in an acromegalic patient with multiple endocrine neoplasia type I syndrome. Cancer, 1988, 62, 445-450.	2.0	30
525	Oncocytomas and null cell adenomas of the human pituitary: Morphometric and in vitro functional comparison. Virchows Archiv A, Pathological Anatomy and Histopathology, 1988, 413, 333-339.	1.4	51
526	Primary thyroid thymoma: A distinct clinicopathologic entity. Human Pathology, 1988, 19, 1463-1467.	1.1	58
527	Human Fetal Adenohypophysis. Neuroendocrinology, 1988, 48, 423-431.	1.2	109
528	Growth Hormone-Releasing Hormone-Producing Tumors: Clinical, Biochemical, and Morphological Manifestations*. Endocrine Reviews, 1988, 9, 357-373.	8.9	265
529	In vitro studies of human pituitary adenomas. Pathology Research and Practice, 1988, 183, 561-564.	1.0	5
530	Pancreatic endocrine tumour producing growth hormone-releasing hormone associated with multiple endocrine neoplasia type I syndrome. European Journal of Endocrinology, 1987, 115, 331-337.	1.9	36
531	OVARIAN TRANSFORMING GROWTH FACTOR-Î± GENE EXPRESSION: IMMUNOHISTOCHEMICAL LOCALIZATION TO THE THECAINTERSTITIAL CELLS. Endocrinology, 1987, 121, 1577-1579.	1.4	128
532	Î±-Transforming Growth Factor in the Bovine Anterior Pituitary Gland: Secretion by Dispersed Cells and Immunohistochemical Localization*. Endocrinology, 1987, 121, 1412-1416.	1.4	92
533	Immunohistologic Localization of Corticotrophin-Releasing Hormone in Human Tumors. American Journal of Clinical Pathology, 1987, 87, 327-333.	0.4	38
534	Lipid Degeneration in Pheochromocytomas Mimicking Adrenal Cortical Tumors. American Journal of Surgical Pathology, 1987, 11, 480-486.	2.1	72
535	Vasoactive intestinal peptide-containing nerves in Peyer's patches. Brain, Behavior, and Immunity, 1987, 1, 148-158.	2.0	69
536	EFFECT OF SMS 201â€“995, A LONGâ€ACTING SOMATOSTATIN ANALOGUE, ON THE SECRETION AND MORPHOLOGY OF A PITUITARY GROWTH HORMONE CELL ADENOMA. Clinical Endocrinology, 1987, 26, 395-405.	1.2	52
537	Gonadotropin Secretion in Vitro by Human Pituitary Null Cell Adenomas and Oncocytomas**. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 1011-1019.	1.8	162
538	Human Fetal Adenohypophysis. Neuroendocrinology, 1986, 43, 308-316.	1.2	94
539	Immunohistological Localization of Growth Hormone-Releasing Hormone in Human Tumors*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 423-427.	1.8	77
540	A Case for Hypothalamic Acromegaly: A Clinicopathological Study of Six Patients with Hypothalamic Gangliocytomas Producing Growth Hormone-Releasing Factor*. Journal of Clinical Endocrinology and Metabolism, 1984, 58, 796-803.	1.8	271

#	Article	IF	Citations
541	Sellar Glomangioma. Ultrastructural Pathology, 1984, 7, 49-54.	0.4	21
542	The influence of pituitary hormones on adjuvant arthritis. Arthritis and Rheumatism, 1984, 27, 682-688.	6.7	119
543	Report of a case of pheochromocytoma producing immunoreactive ACTH and beta-endorphin. Journal of Endocrinological Investigation, 1984, 7, 117-122.	1.8	20
544	Cushing's Disease Associated with an Intrasellar Gangliocytoma Producing Corticotrophin-Releasing Factor. Annals of Internal Medicine, 1984, 101, 789.	2.0	141
545	Leydig Cell Hyperplasia Due to a Testicular Embryonal Carcinoma Producing Human Chorionic Gonadotropin. Andrologia, 1984, 16, 146-155.	1.0	16
546	Pituitary Hormones and Contact Sensitivity in Rats. Allergy: European Journal of Allergy and Clinical Immunology, 1983, 38, 325-330.	2.7	66
547	Immunomodulation by bromocriptine. Immunopharmacology, 1983, 6, 231-243.	2.0	236
548	Histological classification of pituitary disease. Clinics in Endocrinology and Metabolism, 1983, 12, 567-596.	1.8	38
549	Lymphocytic Hypophysitis of Pregnancy Resulting in Hypopituitarism. Obstetrical and Gynecological Survey, 1982, 37, 175-176.	0.2	0
550	The pars tuberalis of the human pituitary. Virchows Archiv A, Pathological Anatomy and Histology, 1982, 399, 49-59.	1.3	72
551	Lymphocytic Hypophysitis of Pregnancy Resulting in Hypopituitarism: A Distinct Clinicopathologic Entity. Annals of Internal Medicine, 1981, 95, 166.	2.0	232
552	Immunohistochemical localization of keratin in craniopharyngiomas and squamous cell nests of the human pituitary. Acta Neuropathologica, 1981, 54, 257-260.	3.9	40
553	Hypothalamic neuronal hamartoma associated with pituitary growth hormone cell adenoma and acromegaly. Acta Neuropathologica, 1980, 52, 231-234.	3.9	81
554	Mechanisms of pituitary tumorigenesis. , 0, , 652-668.		0
555	Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas. , 0, .		29
556	Stage-Sensitive Blockade of Pituitary Somatomammotrope Development by Targeted Expression of a Dominant Negative Epidermal Growth Factor Receptor in Transgenic Mice. , 0, .		8
557	Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary. , 0, .		15
558	Pathology of Tumors of the Thyroid Gland. , 0, , 459-459.		0

#	Article	IF	Citations
559	The pituitary gland. , 0, , 2860-2898.		1
560	Oncologic Outcome Prediction in Differentiated Thyroid Carcinoma: Assumption or Improved Accuracy?. Thyroid, 0, , .	2.4	0